$1.24
+0.02 (+1.23%)
Open$1.23
Previous Close$1.22
Day High$1.24
Day Low$1.17
52W High$9.48
52W Low$1.05
Volume—
Avg Volume19.5K
Market Cap7.99M
P/E Ratio—
EPS$-1.30
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+2,395.5% upside
Current
$1.24
$1.24
Target
$30.82
$30.82
$21.30
$30.82 avg
$34.43
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.77M | 10.40M | 9.97M |
| Net Income | -34,356,212 | 1.68M | 1.79M |
| Profit Margin | -1,940.2% | 16.1% | 17.9% |
| EBITDA | -34,210,763 | 3.32M | 3.17M |
| Free Cash Flow | — | 838.7K | 1.16M |
| Rev Growth | — | +2.0% | -1.5% |
| Debt/Equity | — | 0.33 | 0.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |